biotech

biotech

Source: Sensydia

More than six million U.S. adults are currently living with heart failure. By 2030, that number is expected to climb to nearly 8 million.

Currently, the way to test for heart failure is a painstaking process known as cardiac catheterization.

Simply put, the procedure involves inserting a tiny tube into a blood vessel in someone’s arm or leg and injecting a dye that’s visible to an X-ray. Pressure and flow of blood in the heart are measured, and the photos taken via X-ray show where the heart or arteries are damaged or blocked. Hazards of the process include strokes or heart attacks, tearing arterial lining or blood clots.

Read moreShow less
Evan Xie

Agoura Hills-based clinical biopharmaceutical company Acelyrin went public on the NASDAQ markets May 5, securing one of Los Angeles’ most valuable initial public offerings in two years.

The IPO priced Acelyrin’s 34.5 million shares at $18 apiece, netting the company $621 million. It is now trading under the symbol SLRN.

Read moreShow less
Avenda Health

Last year, the Massachusetts Institute of Technology began testing an artificial intelligence platform called Tempo that used a risk-assessment algorithm to recommend mammogram screenings. By feeding the AI personal health data, including risk factors, existing diagnoses and prior screening information, Tempo was able to recommend to clinicians when to schedule exams for breast cancer.

Read moreShow less
Trending